> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Ingrezza
- URL: https://www.fdaweb.com/regulatory-review-period-for-ingrezza/
- Published: 2020-03-05T12:00:00.000Z
- Updated: 2026-09-14T16:05:59.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5146249

*Federal Register* notice: FDA has determined the regulatory review period for patent extension purposes for Neurocrine Biosciences’ Ingrezza (valbenazine tosylate) indicated for treating adults with tardive dyskinesia. The review period is 2,071 days, which includes 1,827 days that occurred during the testing phase and 244 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-03-05/pdf/2020-04545.pdf?ref=fdaweb.com).